Alterity Therapeutics Limited

NasdaqCM ATHE

Alterity Therapeutics Limited Free Cash Flow Per Share for the year ending June 30, 2024: USD -0.00

Alterity Therapeutics Limited Free Cash Flow Per Share is USD -0.00 for the year ending June 30, 2024, a 58.06% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Alterity Therapeutics Limited Free Cash Flow Per Share for the year ending June 30, 2023 was USD -0.01, a -54.14% change year over year.
Alterity Therapeutics Limited Free Cash Flow Per Share for the year ending June 30, 2022 was USD -0.00, a 53.48% change year over year.
Alterity Therapeutics Limited Free Cash Flow Per Share for the year ending June 30, 2021 was USD -0.01, a -5.13% change year over year.
Alterity Therapeutics Limited Free Cash Flow Per Share for the year ending June 30, 2020 was USD -0.01, a 54.22% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqCM: ATHE

Alterity Therapeutics Limited

CEO	Dr. David A. Stamler M.D.
IPO Date	Sept. 29, 2003
Location	Australia
Headquarters	460 Bourke Street
Employees	10
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Personal Care Vaccines

Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years